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LETTERS TO THE EDITOR
Nifedipine Versus Isosorbide Dinitrate in
Patients With Exertional Angina
Receiving Propranolol
Morse and Nesto (I) have reported that the combination of nifed-
ipine and propranolol is more effective than the combination of
isosorbide dinitrate and propranolol in reducing the incidence of
angina and improving exercise performance. It would be unfor-
tunate if these unwarranted conclusions were to go unchallenged.
Their study clearly demonstrates that when a serious flaw exists
in the basic design, "double-blind crossover comparison" may
afford little justification for drawing sweeping conclusions. In real-
ity, what Morse and Nesto appear to have shown is that maximal
doses of nifedipine to the limits of tolerance are superior to minimal
or relatively low doses of isosorbide dinitrate when these agents
are used in combination with propranolol. The disparity in the
dosage range chosen for the respective drugs is unwittingly made
clear by the authors in their statement that" although only 4 patients
could tolerate the maximal dose of 120 mg/day of nifedipine, 14
tolerated the maximal dose of 120 mg/day of isosorbide dinitrate."
Thus, of the 27 patients with exertional angina in the study, 13
received four daily doses of isosorbide amounting to 20 mg or less
per dose and of these, 7 actually received only 10 mg of the drug
with the same frequency. In three cases, the lowest dose of iso-
sorbide dinitrate (10 mg, four times daily) caused intolerable head-
aches so that premature termination of treatment or crossover to
nifedipine therapy was the final resort. Obviously, such hyper-
sensitivity to the nitrates should have eliminated these subjects
from the study at the outset because their inclusion only served to
bias the results in favor of nifedipine.
The data therefore indicate that only 14 patients of the 27
in the series received isosorbide dinitrate orally in a dosage of
30 mg four times daily. By today's standards even this represents
only a modest amount of the drug, inadequate for optimal thera-
peutic response. For many years the dosage of oral nitrates was
set by arbitrary means and not by careful observation and titration
in human subjects. Through experience, older clinicians recog-
nized that when nitrates are administered by the oral route there
is an attenuation of effect as compared with the responses following
sublingual administration. This loss in potency was known to
encompass all orally administered nitrate compounds and is now
attributed to enzymatic degradation in the liver before drug action
at cardiovascular target sites. To overcome this nullifying influence
and to approach responses possible with sublingual nitrates, in-
ordinately high doses were found to be essential by the oral route.
The long use of "homeopathic" and other ineffectual doses of
oral nitrates has had a "carryover" effect in retarding wide rec-
ognition of therapeutic benefits to be derived from dosage levels
extending to the limits of tolerance.
Despite these considerations, sublingual nitrates are far more
potent than oral nitrates even in massive dosage for the treatment
of stable angina pectoris. Moreover, the additive and often syn-
ergistic response observed when sublingual isosorbide dinitrate is
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used in conjunction with a beta-blocker (2) is a unique phenomenon
that has not been matched to date by any combination of beta-
blocker and calcium channel blocker (3). Until this is fully rec-
ognized, many patients with stable angina are destined to be de-
prived of optimal therapy for this disorder.
A final comment appears indicated concerning the cost of drug
therapy. Nifedipine alone in the dosage range employed by Morse
and Nesto would require an expenditure by the patient of $650 to
$1,000 a year. Isosorbide dinitrate orally (Tembids, 40 mg, four
times daily) or sustained release nitroglycerin (6.5 mg, four times
daily) would cost the patient $100 to $128 for I year's supply.
For the same period of time, sublingual isosorbide dinitrate (5 mg,
four times daily) would cost $56 and a beta-blocker about $152.
In other words, the outlay for nifedipine alone for I year would
amount to two to three times the combined cost of a beta-blocker,
oral nitrate and sublingual isosorbide dinitrate for the same interval
($650 to $1,000 versus $336). From the evidence, the increased
expenditure for nifedipine does not at this time appear warranted
for the treatment of stable angina pectoris responsive to standard
therapy.
HENRY I. RUSSEK,MD,FACC
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Reply
We clearly recognize that nearly half the patients in our study
group probably did not receive what is commonly regarded as
"maximal" nitrate therapy and that those who were advanced to
maximal therapy, as defined in our protocol, may very well have
tolerated even higher dosages. It is for exactly these reasons that
the dosage schedules for individual patients were painstakingly
displayed.
Those patients who received "minimal or relatively low dos-
ages" of isosorbide dinitrate were given those low dosages because
of reported side effects that prevented further upward dose titration.
In a study that is rigidly double-blinded, the investigator (unlike
the experienced clinician) does not have the luxury to interpret as
well as monitor adverse effects and thereby may not confidently
reassure patients that these (adverse effects) will likely subside
with higher doses. For the same reasons, the three patients who
were prematurely crossed over or terminated were allowed to do
so because they simply would not take the drug. We would be
subject to enormous criticism had we, in such a blinded setting,
